Eagle Strategies LLC Raises Position in iShares Biotechnology ETF (NASDAQ:IBB)

Eagle Strategies LLC lifted its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 551.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,674 shares of the financial services provider’s stock after buying an additional 9,883 shares during the quarter. Eagle Strategies LLC’s holdings in iShares Biotechnology ETF were worth $1,602,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IBB. Global Assets Advisory LLC acquired a new stake in iShares Biotechnology ETF in the first quarter valued at approximately $66,059,000. BNP Paribas Financial Markets grew its holdings in iShares Biotechnology ETF by 25.7% during the 1st quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock valued at $282,038,000 after purchasing an additional 420,053 shares in the last quarter. Gray Foundation purchased a new stake in iShares Biotechnology ETF during the 4th quarter worth $17,890,000. Jane Street Group LLC acquired a new position in iShares Biotechnology ETF in the 1st quarter worth $14,386,000. Finally, Miller Investment Management LP lifted its holdings in iShares Biotechnology ETF by 2,394.4% in the 4th quarter. Miller Investment Management LP now owns 90,122 shares of the financial services provider’s stock worth $12,243,000 after buying an additional 86,509 shares in the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Up 0.5 %

Shares of NASDAQ IBB opened at $145.62 on Thursday. iShares Biotechnology ETF has a 1 year low of $111.83 and a 1 year high of $150.17. The stock’s 50-day simple moving average is $144.66 and its 200-day simple moving average is $138.18.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.